Key result
In rabbit models, plasmin achieved equivalent or superior clot lysis compared to TPA and induced no rebleeding (0 of 10 animals) compared to TPA (9 of 10 animals).
Why the study?
Does plasmin improve local thrombolysis without causing hemorrhage compared to tissue plasminogen activator in rabbit models?
Population
Rabbit models of local thrombolysis and fibrinolytic hemorrhage
Comparison
Plasmin (2 or 4 mg/kg intra-arterial infusion) vs Tissue plasminogen activator
Design
Preclinical
Loading...
Plasmin may offer safer local thrombolysis in models; leaves open translation to human use pending trials.
Does plasmin improve local thrombolysis without causing hemorrhage compared to tissue plasminogen activator in rabbit models?
Absolute Event Rate: 0% vs 90%
In a rabbit model, plasmin achieved equivalent or superior local thrombolysis compared to TPA without inducing fibrinolytic hemorrhage, suggesting a favorable safety profile.
A 2001 study studied Thrombosis and fibrinolytic hemorrhage (rabbit models) (n=20). Plasmin vs. Tissue plasminogen activator (TPA) (1 or 2 mg/kg) was evaluated on Rebleeding from prior puncture sites in the earpuncture rebleed model. In rabbit models, plasmin achieved equivalent or superior clot lysis compared to TPA and induced no rebleeding (0 of 10 animals) compared to TPA (9 of 10 animals).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: